Humoral theory of transplantation: Further evidence

Current Opinion in Immunology

Volumn 17, Issue 5, 2005, Pages 541-545

  Terasaki, Paul I ^a   Cai, Junchao ^a  

^a TERASAKI FOUNDATION LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIBODY;

ANTIBODY RESPONSE; GRAFT DYSFUNCTION; HUMAN; HYPERACUTE GRAFT REJECTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; REVIEW; TRANSPLANTATION;

ANTIBODY FORMATION; GRAFT REJECTION; HLA ANTIGENS; HUMANS; TRANSPLANTATION IMMUNOLOGY;

EID: 23944450383     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2005.07.018     Document Type: Review

References (34)

1. P.I. Terasaki Humoral theory of transplantation Am J Transplant 3 2003 665 673
2. J. Cai, and P.I. Terasaki Humoral theory of transplantation-Mechanism, prevention, and treatment Hum Immunol 66 2005 334 342
3. Y. Iwaki, and P.I. Terasaki Primary nonfunction in human cadaver kidney transplantation: evidence for hidden hyperacute rejection Clin Transplant 1 1987 125 131
4. D.J. Cook, P.I. Terasaki, Y. Iwaki, G.Y. Terashita, and M. Lau An approach to reducing early kidney transplant failure by flow cytometry crossmatching Clin Transplant 1 1987 253 256
5. K. Ogura, P.I. Terasaki, C. Johnson, R. Mendez, J.T. Rosenthal, R. Ettenger, D.C. Martin, E. Dainko, L. Cohen, and T. Mackett The significance of a positive flow cytometry crossmatch test in primary kidney transplantation Transplantation 56 1993 294 298
6. H.M. Gebel, R.A. Bray, and P. Nickerson Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk Am J Transplant 3 2003 1488 1500
7. T.E. Starzl, R.A. Lerner, F.J. Dixon, C.G. Groth, L. Brettschneider, and P.I. Terasaki Shwartzman reaction after human renal homotransplantation N Engl J Med 278 1968 642 648
8. B. Gollackner, S.K. Goh, I. Qawi, L. Buhler, C. Knosalla, S. Daniel, E. Kaczmarek, M. Awwad, D.K. Cooper, and S.C. Robson Acute vascular rejection of xenografts: roles of natural and elicited xenoreactive antibodies in activation of vascular endothelial cells and induction of procoagulant activity Transplantation 77 2004 1735 1741
9. H.E. Feucht, H. Schneeberger, G. Hillebrand, K. Burkhardt, M. Weiss, G. Riethmuller, W. Land, and E. Albert Capillary deposition of C4d complement fragment and early renal graft loss Kidney Int 43 1993 1333 1338
10. Q. Zhang, L.W. Liang, D.W. Gjertson, C. Lassman, A.H. Wilkinson, E. Kendrick, P.T. Pham, G.M. Danovitch, H.A. Gritsch, and E.F. Reed Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction Transplantation 79 2005 591 598 Antibody development and diagnosis of acute rejections are combined in this study.
11. D.D. Koo, I.S. Roberts, I. Quiroga, J. Procter, M.C. Barnardo, M. Sutton, L. Cerundolo, D.R. Davies, P.J. Friend, P.J. Morris, and S.V. Fuggle C4d deposition in early renal allograft protocol biopsies Transplantation 78 2004 398 403
12. R.D. Poduval, P.V. Kadambi, M.A. Josephson, R.A. Cohn, R.C. Harland, B. Javaid, D. Huo, J.R. Manaligod, J.R. Thistlethwaite, and S.M. Meehan Implications of immunohistochemical detection of C4d along peritubular capillaries in late acute renal allograft rejection Transplantation 79 2005 228 235 Identified evidence of acute cellular with acute humoral rejection in more than 40% of late acute episodes using C4d staining.
13. A.L. Girnita, R. Duquesnoy, S.A. Yousem, A.T. Iacono, T.E. Corcoran, M. Buzoianu, B. Johnson, K.J. Spichty, J.H. Dauber, and G. Burckart HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction Am J Transplant 5 2005 131 138 The authors show the importance of HLA-specific antibodies in both acute and chronic rejection in lung transplantation.
14. R.N. Mitchell Allograft arteriopathy: pathogenesis update Cadiovasc Pathol 13 2004 33 40
15. A. Dorling, C. Stocker, T. Tsao, D.O. Haskard, and R.I. Lechler In vitro accommodation of immortalized porcine endothelial cells: resistance to complement mediated lysis and down-regulation of VCAM expression induced by low concentrations of polyclonal human IgG antipig antibodies Transplantation 62 1996 1127 1136
16. A.D. Salama, A. Delikouras, C.D. Pusey, H.T. Cook, G. Bhangal, R.I. Lechler, and A. Dorling Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody Am J Transplant 1 2001 260 269
17. K. Narayanan, A. Jaramillo, D.L. Phelan, and T. Mohanakumar Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway Eur J Immunol 34 2004 2303 2312 Together with [16], the authors demonstrate that exposure of endothelial cells to sub-saturating concentrations of HLA-specific antibodies confers resistance towards antibody/complement-mediated lysis - a process termed accommodation.
18. K. Takahashi, K. Saito, S. Takahara, A. Okuyama, K. Tanabe, H. Toma, K. Uchida, A. Hasegawa, N. Yoshimura, and Y. Kamiryo Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan Am J Transplant 4 2004 1089 1096
19. P.I. Terasaki, and M. Ozawa Predicting kidney graft failure by HLA antibodies: a prospective trial Am J Transplant 4 2004 438 443 International prospective study of 4763 patients from 36 centers demonstrating the role of HLA antibodies in predicting late graft loss.
20. Terasaki PI, Ozawa M: Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation in press. The authors show that, together with serum creatinine, antibody is a powerful predictor of graft survival.
21. E.R. Vasilescu, E.K. Ho, L. de la Torre, S. Itescu, C. Marboe, R. Cortesini, N. Suciu-Foca, and D. Mancini Anti-HLA antibodies in heart transplantation Transpl Immunol 12 2004 177 183 Demonstrates a significant correlation between anti-HLA class II antibodies and transplant-related coronary artery disease.
22. S. Jordan, C. Cunningham-Rundles, and R. McEwan Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications Am J Transplant 3 2003 653 664
23. I. Monteiro, L.M. McLoughlin, A. Fisher, A.N. de la Torre, and B. Koneru Rituximab with plasmapheresis and splenectomy in ABO-incompatible liver transplantation Transplantation 76 2003 1648 1649
24. G. Tyden, G. Kumlien, and I. Fehrman Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab Transplantation 76 2003 730 731
25. C.J. Sonnenday, D.S. Warren, M. Cooper, M. Samaniego, M. Haas, K.E. King, R.S. Shirey, C.E. Simpkins, and R.A. Montgomery Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy Am J Transplant 4 2004 1315 1322
26. C.A. Vieira, A. Agarwal, B.K. Book, R.A. Sidner, C.M. Bearden, H.M. Gebel, A.L. Roggero, N.S. Fineberg, T. Taber, M.A. Kraus, and M.D. Pescovitz Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics Transplantation 77 2004 542 548
27. Y.T. Becker, B.N. Becker, J.D. Pirsch, and H.W. Sollinger Rituximab as treatment for refractory kidney transplant rejection Am J Transplant 4 2004 996 1001
28. T.C. Pearson, J. Trambley, K. Odom, D.C. Anderson, S. Cowan, R. Bray, A. Lin, D. Hollenbaugh, A. Aruffo, and A.W. Siadak Anti-CD40 therapy extends renal allograft survival in rhesus macaques Transplantation 74 2002 933 940
29. C.P. Larsen, T.C. Pearson, A.B. Adams, P. Tso, N. Shirasugi, E. Strobertm, D. Anderson, S. Cowan, K. Price, and J. Naemura Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties Am J Transplant 5 2005 443 453 New variant of CTLA4-Ig (LEA29Y) is found to be very effective in prolonging grafts and reducing donor specific antibodies.
30. M.L. Rose, J. Smith, G. Dureau, A. Keogh, and J. Kobashigowa Mycophenolate mofetil decreases antibody production after cardiac transplantation J Heart Lung Transplant 21 2002 282 285
31. P. Merville, F. Berge, C. Deminiere, D. Morel, G. Chong, D. Durand, L. Rostaing, G. Mourad, and L. Potaux Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil Am J Transplant 4 2004 1769 1775
32. C. Dudley, E. Pohanka, H. Riad, J. Dedochova, P. Wijngaard, C. Sutter, H.T. Silva Jr. Mycophenolate Mofetil Creeping Creatinine Study Group Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the 'creeping creatinine' study Transplantation 79 2005 466 475
33. M. Gonzalez Molina, D. Seron, R. Garcia del Moral, M. Carrera, E. Sola, M. Jesus Alferez, P. Gomez Ullate, L. Capdevila, and M.A. Gentil Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative StUdy Group of Chronic Allograft Nephropathy Transplantation 77 2004 215 220
34. P.I. Terasaki Deduction of the fraction of immunologic and non-immunologic failure in cadaver donor transplants Clin Transpl 2003 449 452